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Abstract
Background: Colorectal cancer (CRC) represents a serious health care problem in the Czech Republic, introducing
a need for a prospective modelling of the incidence and prevalence rates. The prevalence of patients requiring
anti-tumour therapy is also of great importance, as it is directly associated with planning of health care resources.
Methods: This work proposes a population-based model for the estimation of stage-specific prevalence of CRC
patients who will require active anti-tumour therapy in a given year. Its applicability is documented on records of
the Czech National Cancer Registry (CNCR), which is used to estimate the number of patients potentially treated
with anti-tumour therapy in the Czech Republic in 2015.
Results: Several scenarios are adopted to cover the plausible development of the incidence and survival rates, and
the probability of an anti-tumour therapy initiation. Based on the scenarios, the model predicts an increase in CRC
prevalence from 13% to 30% in comparison with the situation in 2008. Moreover, the model predicts that 10,074
to 11,440 CRC patients will be indicated for anti-tumour therapy in the Czech Republic in 2015. Considering all
patients with terminal cancer recurrence and all patients primarily diagnosed in stage IV, it is predicted that 3,485
to 4,469 CRC patients will be treated for the metastatic disease in 2015, which accounts for more than one third
(34-40%) of all CRC patients treated this year.
Conclusions: A new model for the estimation of the number of CRC patients requiring active anti-tumour therapy is
proposed in this paper. The model respects the clinical stage as the primary stratification factor and utilizes solely the
population-based cancer registry data. Thus, no specific hospital data records are needed in the proposed approach.
Regarding the short-term prediction of the CRC burden in the Czech Republic, the model confirms a continuous
increase in the burden that must be accounted for in the future planning of health care in the Czech Republic.
Background
The Czech population, with an annually diagnosed 78.7
colorectal cancer (CRC) patients per 100,000 inhabitants
(2008), presently occupies an undesirable 3rd position in
international statistics of age-standardised CRC inci-
dence rates [1]. Moreover, the number of newly diag-
nosed cases is supposed to be high in the future as well,
namely due to population ageing. This health care pro-
blem is further worsened by the fact that a large propor-
tion of colorectal carcinomas are primarily diagnosed in
a metastatic stage (25% in 2008) [2].
Thus, there is a strong need for a prospective model-
ling of CRC incidence and prevalence rates, as these
measures are necessary for monitoring of the overall
cancer load and its dynamics [3]. The prospective esti-
mates should also enable us to quantify the resources
necessary for the health care system [4], provided that
we are able to adjust the rates for patients untreated for
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refusal of treatment, very advanced stage of disease or
unfavourable health status of ap a t i e n t ,e t c . ) .T h ee x i s t -
ing models use either only population data [5]or a com-
bination of population data and clinical records [6,7]. In
the former case, the model does not employ a concept
of cancer recurrence, whereas in the latter case, the con-
cept of cancer recurrence is considered and the particu-
lar rates are estimated from the hospital records.
The objective of this paper is to propose a new model
for the estimation of the number of CRC patients
requiring active anti-tumour therapy that is fully based
on the population-based cancer registry data. The model
uses the population data for identification of all its com-
ponents, i.e. also for the quantification of cancer recur-
rence rates. Moreover, the proposed model is stage-
specific and as such it respects the disease extent at the
time of primary diagnosis. The stage-specific estimates
of the CRC burden can be regarded as the main added
value of this paper. This paper does not focus on the
specific anti-tumour therapies as well as their combina-
tions. The reason for this is that the use of population
data is not sufficient for proper characterisation and
quantification of the individual treatment modalities.
Thus, the anti-tumour therapy is considered rather as a
whole. On the other hand, the information on use of
the individual treatment modalities is partially included
within the information on stage-specific CRC burden as
the clinical stage closely correlates with particular thera-
peutic procedures. The model is finally applied to the
Czech population data and provides the estimates of
CRC patients treated in the Czech Republic in 2015.
Methods
Patients
The Czech Republic makes use of high-quality popula-
tion-based data on cancer epidemiology. The Czech
National Cancer Registry (CNCR) covers the whole
population of the Czech Republic (10,230,000 inhabi-
tants according to the 2001 census) since 1976. The
registration of cancer cases is prescribed by law and it is
therefore obligatory. Until the end of 2008, there were
almost 1.7 million cancer cases recorded in the CNCR.
A total of 179,286 incident CRC cases (12% of the
CNCR records) were registered in the period 1982-2008.
Cancer location was defined according to the Interna-
tional Classification of Diseases [8]. ICD-10 codes C18,
C19, and C20 were considered as CRC cases. Regarding
only CRC as the cancer of interest, the completeness of
CRC prevalence in the CNCR can be estimated, using
the model-based method utilising the observed and
modelled CRC prevalence [9], to be approximately 97%
in 2008. The CNCR records on cancer as the main
cause of death were verified against the Czech Database
of Death Records, a database administered by the Czech
Statistical Office [10].
Only clinically relevant cancer records entered the
modelling procedures. Data on cases diagnosed in 1977-
1981 were excluded due to the lack of a classification
system for clinical stages. The epidemiological records
on patients diagnosed by death certificate only (3,943
cases in total, 2% of all incident CRC cases) or at
autopsy (7,184 cases in total, 4% of all incident CRC
cases) were excluded from the analysis as well. Finally,
160,017 incident cases were considered for the analysis,
38% younger than 65 years, and 57% males.
Four age categories were considered in the modelling:
0-49 years, 50-64 years, 65-79 years and 80+ years; as
well as three categories for the disease extent: clinical
stages I and II, representing localised CRC, clinical stage
III, representing regionally advanced disease, and clinical
stage IV, representing metastatic disease. Colorectal can-
cers in stages I and II were merged prior to analyses due
to changes in the TNM classification system [11]. More-
over, cases with missing information on stage (denoted
as X) were also considered for the model, as they repre-
sent an indispensable mass of patients that needs to be
accounted for in the health care system.
Active anti-tumour therapy was defined on the basis
of the CNCR records as causal therapy; symptomatic
therapy was not considered. This definition includes
surgery, radiotherapy, chemotherapy, hormonal therapy,
targeted therapy, and immunotherapy [12].
The proposed model concept
The concept comes from the model of time interval pre-
v a l e n c e ,an u m b e ro fp a t i e n t sw h ob o t hh a v eap r e s e n t
or past diagnosis of CRC and are alive in a population
during a certain period. In this part of the paper, for the
sake of formula simplicity, we consider only the case of
one particular age group. The overall number of preva-
lent cases across all age groups can easily be estimated
as a sum of predictions over individual age categories.
Regarding the extent of cancer, denoted with s (s =I+
II, III, IV and X), the stage-specific prevalence in calen-
dar year y can be expressed as follows:
Ps(y)=Is(y)+
n 
i=1
Is(y − i)Ss(i). (1)
Here Is(y-i ) denotes the stage-specific incidence at i
years prior to the calendar year y, Ss(i) is the corre-
sponding i-year survival rate, and n is the maximum fol-
low-up in the population-based registry in years (given
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process). Note that the first term on the right-hand side
of equation (1) represents the number of newly diag-
nosed patients in year y, whereas the second term stands
for the number of living patients diagnosed in the past,
which is estimated as the convolution of the incidence
rates and the appropriate patients’ survival rates.
To obtain the number of treated patients, the first term
of equation (1) needs to be further corrected for the
probability of being untreated with anti-tumour therapy
due to poor health condition or other objective reasons,
and, simultaneously, the second term of equation (1)
needs to be corrected in a way that the only patients con-
sidered are those with the recurrence of the disease in a
good health condition to allow for anti-tumour treat-
ment. The prevalence of patients receiving active anti-
tumour therapy can then be written as follows:
P∗
s (y)=Is(y)δs(y)+
n 
i=1
Is(y − i)Ss(i)Rs(i)δs(y). (2)
Here δs(y) is the stage-specific probability of being trea-
ted with an anti-tumour treatment in the year y and Rs(i)
is a function that describes the probability of cancer recur-
rence after surviving i years after primary diagnosis.
The cancer recurrence function, Rs(i), is further speci-
fied using the following consideration: each patient diag-
nosed in stage s c a ns u f f e ri nt i m ef r o mt w of o r m so f
cancer recurrence, either non-terminal (actually not
leading to death in the year y, denoted as Rs
1(i)), or
terminal (leading to death in the year y, denoted as Rs
2
(i)). The stratification further determines the patient’s
treatment course. In the former case, it is assumed that
the patient is treated in a similar way as at the time of
primary diagnosis, i.e. the patient stays in the prevalence
pool of the particular stage s. In the second case, it is
assumed that the patient is treated for metastatic dis-
ease, i.e. the patient moves from the prevalence of stage
I + II, III or X to the prevalence of stage IV.
Splitting the Rs(i)t e r mi ne q u a t i o n( 2 ) ,a n dm o v i n g
the patients suffering from terminal cancer recurrence
to the prevalence of stage IV, led to the following for-
mulation of the stage-specific prevalence of patients
requiring active anti-tumour therapy:
P∗
s (y)=Is(y)δs(y)+
n 
i=1
Is(y − i)Ss(i)R1
s (i)δs(y); s = I + II,III,X(3)
P∗
IV(y)=IIV(y)δIV(y)+
n 
i=1
IIV(y − i)SIV(i)

R1
IV(i)+R2
IV(i)

δIV(y)
+

s=I+II,III,X
n 
i=1
Is(y − i)Ss(i)R2
s (i)δIV(y).
(4)
It should be noted that the probability of being treated
is assumed to be the same in all patients primarily diag-
nosed with stage IV cancer, denoted as δIV(y), irrespec-
tive of whether they are newly diagnosed or suffer from
non-terminal or terminal cancer recurrence, respectively.
On the other hand, in patients primarily diagnosed with
stage s = I + II, III or X, the stage-specific probability of
being treated is assumed to be the same, and denoted as
δs(y), only in newly diagnosed patients and those
patients suffering from non-terminal cancer recurrence.
In patients estimated to suffer from terminal cancer
recurrence who are supposed to move from the preva-
lence of stage I + II, III or X to the prevalence of stage
IV, we assume the probability of being treated to be
equal to that of patients primarily diagnosed with stage
IV cancer, i.e. equal to δIV(y).
Specifying colorectal cancer incidence and survival
Two scenarios are considered for the estimation of inci-
dence rates. First, CRC incidence rates are considered
fixed at the values observed in 2008; second, the age,
period and cohort model is applied for the estimation
[13]. In the proposed model, the age-drift Poisson
regression models are applied employing two different
link functions: the identity link function is used to
model increasing incidence trends, whereas the logarith-
mic link is used to model decreasing trends [14].
The stage-specific survival rates are estimated using a
method based on the moving window principle that
employs the standard life-table method [15]. In this
procedure, the survival rates are estimated successively,
using the cohort analysis of patients diagnosed in over-
lapping 5-year time intervals. To ensure validity, calcu-
lation of x-year survival rates is only performed on
cohorts in whom the x-year survival rate can be reli-
ably estimated, and were diagnosed as recently as pos-
sible [16]. Two scenarios are adopted regarding
survival estimates. In the first scenario, the survival
rates are assumed to improve from 2008 to 2015 in
the same manner as observed in the CNCR data from
the period of 2004-2008. In the second scenario, survi-
val rates needed for calculating the 2009-2015 preva-
lence are fixed at the most recent values, i.e. survival
rates in 2008.
Colorectal cancer recurrence
The records of cancer recurrence rates are not directly
available on the population level in the Czech Republic.
For this reason, we use surrogate parameters to estimate
the cancer recurrence rates. Regarding non-terminal
cancer recurrence, Rs
1(i), it is estimated using the fol-
low-up information on the patient’sv i t a ls t a t u s
(recorded as alive or dead) and the information on cau-
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the first year following diagnosis (the very first year after
diagnosis is assumed to correspond to the initial treat-
ment phase [17]). This information is extracted from
the CNCR Follow-up Reports that represent obligatory
monitoring of cancer patients in the Czech Republic in
t i m e .W es i m p l ya s s u m et h a tar e c o r do no t h e rt h a n
symptomatic therapy in a particular year after diagnosis
indicates that the patient is treated in this year due to
an objective reason, i.e. due to the return of cancer.
However, as the Rs
1(i) function refers only to non-term-
inal cancer recurrence, an additional condition is neces-
sary, namely that the patients must be alive at the end
of the particular year of interest, i.e. the cancer recur-
rence must not be terminal in a given year. This condi-
t i o ni sa p p l i e dt oe n s u r et h a tt h ep a t i e n ti sn o ti na
terminal (metastatic) stage of CRC in the year of inter-
est. The Rs
1(i) function is estimated from the yearly Fol-
low-up Reports using the standard life-table method.
As for terminal cancer recurrence, the Rs
2(i)f u n c t i o n
is estimated using the information on cancer as the
main cause of death. The approach is based on the sim-
plifying assumption that nobody can die from cancer,
with cancer being the main reason of death, without
passing through the phase of metastatic disease. In
other words, we assume that even a patient diagnosed
with stage I CRC is treated as metastatic (stage IV) in a
given year when cancer is recorded as his cause of
death. The Rs
2(i) function thus represents the excess
mortality of the colorectal cancer, i.e. the difference
between the total mortality experienced by the CRC
patients and the expected mortality of a comparable
group from the general population, and can be thus spe-
cified using either the relative survival function or the
underlying excess hazard rate [18]. Both of these
quantities are derived using the mixture cure survival
model adjusted for background mortality [19].
As the last factor needed for the model, the age- and
stage-specific proportions of patients treated with anti-
tumour therapy are derived from the CNCR population
data. Just as in the case of incidence and survival rates,
two scenarios are considered for the proportion of the
treated CRC patients. First, this proportion is regarded
as fixed and estimated in a stage-specific manner from
the period 2004-2008. Second, the values observed from
the CNCR are extrapolated forward in time using a
logistic regression model.
For the sake of completeness, the eight models consid-
ered in this paper that are defined by combination of
two scenarios for the estimation of incidence rates
(fixed and modelled, respectively), two scenarios for the
estimation of survival rates (constant and improving,
respectively), and two scenarios for the proportion of
treated patients (fixed and modelled, respectively) are
summarised in Table 1. All computations were per-
formed using Stata 10.1 software [20].
Results
Figure 1 shows the observed and predicted values of
one-year CRC prevalence in the Czech Republic. In
order to simplify the results, only the lowest and the
highest estimates coming from the four scenarios that
reflect different trends in incidence and survival rates
are displayed. The lowest estimates have been obtained
for all stages when applying the scenarios with constant
survival rates. The highest estimates for stages I + II
and patients with missing information on stage have
been obtained by applying the scenario with constant
incidence and improving survival rates, whereas the
highest estimates for stage III and stage IV have been
Table 1 Description of the eight scenarios used to estimate the number of colorectal cancer patients treated with anti-
tumour therapy in 2015 in the Czech Republic
Proportion of treated patients
(for the year 2015)
Incidence rates
(for the period 2009-2015)
Survival rates
(for the period 2009-2015)
Survival rates are considered
fixed at the most recent values,
i.e. survival rates in 2008
Survival rates are assumed to
improve in the same manner as
observed in the period 2004-2008
Proportion is regarded fixed in time and
estimated from the period 2004-2008
Incidence rates are considered
fixed at the values observed in
2008
Scenario 1 Scenario 2
Incidence rates are modelled in
time using the age-drift
Poisson regression model
Scenario 3 Scenario 4
Proportion observed in the period 2004-
2008 is extrapolated forward in time
using a logistic regression model
Incidence rates are considered
fixed at the values observed in
2008
Scenario 5 Scenario 6
Incidence rates are modelled in
time using the age-drift
Poisson regression model
Scenario 7 Scenario 8
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dence and improving survival rates. As expected, the
biggest discrepancy between the scenarios can be seen
for the merged stages I + II where the improvements in
survival are manifested the most. In 2015, the CRC pre-
valence of patients primarily diagnosed in stage I or II is
estimated as ranging between 338.8 and 389.8 per
100,000 people, while the prevalence of patients diag-
nosed in stage III is estimated as ranging between 114.1
and 150.2 per 100,000 people, and the prevalence of
patients diagnosed in stage IV ranging between 50.7 and
58.1 per 100,000 people. The prevalence of CRC
patients with missing information on stage in CNCR is
estimated as ranging between 26.3 and 33.9 per 100,000
people. In total, between 529.9 and 632.0 CRC patients
per 100,000 people are estimated to be prevalent in
2015. The model thus predicts an increase in CRC pre-
valence from 13% to 30% in comparison with the situa-
tion in 2008. This increase underlines the seriousness of
the colorectal cancer burden in the Czech Republic.
Figure 2 shows the estimated stage-specific rates of
non-terminal and terminal cancer recurrence, respec-
tively; in the ten years following the first completed year
after diagnosis (the first year after diagnosis is consid-
ered to correspond to primary therapy). The estimates
corresponding to the most recent time period, 1995-
2008, are shown. We can see the risk of non-terminal
cancer recurrence gradually decreasing in the first three
years and reaching the 3% level in all stages afterwards.
On the contrary, the pattern of terminal recurrence
rates varies with clinical stage up to five years after diag-
nosis; in stages I + II, the recurrence rates are consis-
tently below 7%, conveying a good perspective of
patients diagnosed with less advanced disease. In stage
III, the terminal recurrence rate shows a stable but very
slow decrease in time. The terminal recurrence rate for
stage IV reveals a very high risk of dying from CRC
exceeding even 60% after the first year following diagno-
sis. The risk reaches the level comparable to other
stages after 5-6 years following the diagnosis. The term-
inal recurrence rate of the patients with missing infor-
mation on stage is located in the middle of the other
stage-specific profiles (Figure 2). It documents the fact
that patients with missing information on stage repre-
sent a mixture of patients of all stages.
Based on CNCR data, the proportion of patients who
are given non-symptomatic anti-tumour treatment in
stages I + II and III is continually high (above 95%) and
stable in time (data not shown). The only exception is
the group of elderly patients (80+ years), where the
Figure 1 Observed and predicted values of colorectal cancer prevalence in the Czech Republic per 100,000 people according to
clinical stage of primary tumour.
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the other hand, we can see a change in the probability
of an anti-tumour therapy administration in patients
treated for CRC in stage IV. We have estimated the
shift in the proportion of treated stage IV patients
between the period 2004-2008 and the year 2015 to be
from 3% (a change from 90% in the period 2004-2008
to 93% estimated for the year 2015) in the age group 0-
49 years up to 18% (a change from 44% to 62%) in the
age group 80+ years.
The numbers of patients requiring active anti-tumour
therapy for the CRC in the Czech Republic in 2015 esti-
mated according to eight considered scenarios are given
in Table 2. For each scenario, the first three columns
represent the individual components of the proposed
model: the estimated number of newly diagnosed and
treated patients, the estimated number of patients trea-
ted for non-terminal cancer recurrence, and the esti-
mated number of patients treated for terminal cancer
recurrence, respectively. Then, the sums with respect to
the stage at the diagnosis are shown (column 4).
In total, from 10,074 to 11,440 CRC patients are pre-
dicted for anti-tumour therapy administration in the
Czech Republic in 2015 according to the eight scenarios
considered for incidence and survival rates and the
probability of anti-tumour therapy administration.
When regarding the stage at diagnosis as the primary
stratification factor, 4,595 to 4,828 patients (41-47% of
all CRC patients) primarily diagnosed in stage I or II;
2,679 to 3,613 patients (27-32%) primarily diagnosed in
stage III; and 2,366 to 2,969 patients (23-27%) primarily
diagnosed in stage IV are estimated to be treated in
2015, respectively. Regarding patients with missing
information on stage, 134 to 335 of them (1-3%) are
predicted for anti-tumour therapy in 2015.
Regarding the overall number of patients treated in
stage IV in 2015, the patients with terminal cancer
recurrence primarily diagnosed in stages I, II or III and
the patients with missing information on stage also need
to be added to the number of patients primarily diag-
nosed in stage IV, because they are treated for the meta-
static disease, as well. In this case, 3,485 to 4,469 CRC
patients are predicted to be treated for the metastatic
disease, which accounts for more than one third (34-
40%) of all CRC patients that are estimated to be treated
in 2015 in the Czech Republic.
Discussion
Modelling the prevalence of the CRC patients requiring
active anti-tumour therapy is an important issue [4-7],
especially in countries like the Czech Republic which
ranks among countries with the highest cancer load
worldwide [1]. Moreover, the effort to estimate the pre-
valence on a stage-specific basis is a challenging task
and, to our knowledge, there is relatively little informa-
tion on this subject in the literature [21]. The stage-spe-
cific modelling is complicated and requires a
comprehensive approach, since the stage at the time of
diagnosis need not necessarily coincide with the disease
extent several years afterwards. The disease extent
should be taken into account in the modelling process
at all time points because the clinical stage is, in regards
to patient life-expectation and anticipated financial
costs, even more important than age at diagnosis [22].
T h a ti sw h yw ea t t e m p tt op r o p o s eac o m p r e h e n s i v e
statistical method here that may provide such estimates
Figure 2 Stage-specific estimates of non-terminal and terminal recurrence rates in first ten years after primary diagnosis of colorectal
cancer; the estimates correspond to the recent time period, 1995-2008.
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tion-based cancer registry data.
The cancer prevalence estimation is not straightfor-
w a r d ,a si tc a n n o tb ee s t i m a t e dd i r e c t l yf r o mt h ep o p u -
lation-based data due to time limited registration, and
thus it has to be modelled. Several methods have been
proposed for estimating the future cancer burden
based on different modelling strategies, of which the
back-calculation method, combining parametric esti-
mates of incidence and survival, is the most frequently
used [23,24]. Other approaches include the calculation
of individual likelihoods of living with cancer [25], the
application of the Markov model [26] or the applica-
tion of the Bayesian model [27]. The generalization of
the completeness index method first introduced by
Capocaccia & De Angelis [9] has also been applied
[28]. In our model, we also use the back-calculation
method. The incidence rates are estimated using an
age-drift model [13,29] whereas the survival rates are
estimated using a modification of the standard life-
table method [16].
In accordance with other epidemiological studies, for
example [23], four extreme scenarios regarding progress
in incidence and survival rates are implemented to
Table 2 Stage-specific estimates of prevalence of patients requiring active anti-tumour therapy for colorectal cancer in
the Czech Republic in 2015 according to the eight scenarios
Scenario 1: Constant proportion of treated patients;
Constant incidence rate; Constant survival rates
Scenario 2: Constant proportion of treated patients;
Constant incidence rate; Improving survival rates
Stage at
diagnosis
Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total
Stage I+II 3,650 565 479 4,694 3,650 607 524 4,781
Stage III 1,783 355 541 2,679 1,783 407 625 2,815
Stage IV 1,419 181 766 2,366 1,419 212 898 2,529
Missing 220 16 99 335 220 13 76 309
All cases 7,072 1,117 1,885 10,074 7,072 1,239 2,123 10,434
Scenario 3: Constant proportion of treated patients;
Modelled incidence rate; Constant survival rates
Scenario 4: Constant proportion of treated patients;
Modelled incidence rate; Improving survival rates
Stage at
diagnosis
Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total
Stage I+II 3,581 547 467 4,595 3,581 589 511 4,681
Stage III 2,223 422 632 3,277 2,223 475 725 3,423
Stage IV 1,428 177 761 2,366 1,428 207 892 2,527
Missing 131 10 59 200 131 9 47 187
All cases 7,363 1,156 1,919 10,438 7,363 1,280 2,175 10,818
Scenario 5: Modelled proportion of treated patients;
Constant incidence rate; Constant survival rates
Scenario 6: Modelled proportion of treated patients;
Constant incidence rate; Improving survival rates
Stage at
diagnosis
Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total
Stage I+II 3,613 560 562 4,735 3,613 602 613 4,828
Stage III 1,831 362 628 2,821 1,831 415 727 2,973
Stage IV 1,675 206 890 2,771 1,675 241 1,038 2,954
Missing 122 9 121 252 122 7 92 221
All cases 7,241 1,137 2,201 10,579 7,241 1,265 2,470 10,976
Scenario 7: Modelled proportion of treated patients;
Modelled incidence rate; Constant survival rates
Scenario 8: Modelled proportion of treated patients;
Modelled incidence rate; Improving survival rates
Stage at
diagnosis
Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total Newly diagnosed
patients
Non-terminal cancer
recurrence
Terminal
cancer
recurrence
Total
Stage I+II 3,542 544 549 4,635 3,542 583 599 4,724
Stage III 2,285 429 734 3,448 2,285 484 844 3,613
Stage IV 1,697 203 887 2,787 1,697 236 1,036 2,969
Missing 72 5 71 148 72 5 57 134
All cases 7,596 1,181 2,241 11,018 7,596 1,308 2,536 11,440
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rates are either assumed fixed at the 2008 level or mod-
elled using the age, period, and cohort model. As for
the survival rates, they are either assumed to improve
from 2008 to 2015 at the same rate as observed in the
period of 2004-2008 or fixed at the most recent values,
i.e. the survival rates available in 2008.
The impact of the different scenarios on the CRC pre-
valence is the most remarkable in stages I + II and III,
and almost negligible in stage IV. Considering the inci-
dence profiles of individual CRC stages [2], we can say
that improving survival rates also play a crucial role in
driving CRC prevalence. The results document the
improvements in cancer survival of less advanced CRC
that have been achieved in the Czech Republic in the
last decade [30]. On the other hand, it also documents
the fact that the treatment of CRC in clinical stage IV
continues to present a formidable challenge.
The estimated one-year prevalence rates are not
directly comparable with the international data coming
from comparative studies such as [31], since these stu-
dies focus primarily on the point prevalence. However,
at least a crude comparison shows that the prevalence
of CRC in the Czech Republic gradually reaches the
situation in the Western and Northern European coun-
tries. A very high incidence rate and the already men-
tioned successively improving survival rates can be
regarded as the two main drivers.
The issue of stage-specific estimation of CRC preva-
lence can be considered controversial due to the non-
trivial association between the stage at diagnosis and the
gradual progress of cancer during the follow-up period.
Cancer recurrence rates of patients diagnosed in the
past and living in the year of interest are thus by all
means the most appealing and most arguable compo-
nents of the model. Our simplifying assumption of two
forms of cancer recurrence is motivated by the financial
aspects of cancer care. The separation of patients with
terminal cancer recurrence is needed as the treatment
of metastatic disease is significantly more costly than
the treatment of non-terminal disease [22].
Two principal types of estimates for the cancer
recurrence rates are widely used, either estimates
based on clinical or hospital data [32-35] or estimates
coming from population-based databases [36,37]. We
feel that the estimates coming from the population-
based databases may be more appropriate in this type
of modelling, as the estimates calculated from hospital
data can lead to biased results due to non-representa-
tiveness of the underlying set of patients. On the other
hand, the precise information on time of cancer recur-
rence is barely available in the population-based cancer
registries. In our model, the rationale behind the esti-
mation of functions representing the non-terminal and
terminal cancer recurrence rates, respectively, is to use
surrogate parameters. The terminal form of cancer
recurrence is estimated from the information on can-
cer as the main cause of death, whereas the non-term-
inal form is identified from the information on
patient’s vital status and anti-tumour therapy applied
during the follow-up period. The need for the surro-
gate information introduces high requirements on the
data quality of the population-based registry. A possi-
b l ep r o b l e mw i t ht h et e r m i n a lc a n c e rr e c u r r e n c er a t e
estimation can be seen in patients whose CNCR record
does not include cancer as the main cause of death,
but who, in fact, died of cancer. Such patients would
cause underestimation of the true terminal cancer
recurrence rates; however, this problem is marginal in
t h eC N C Rd a t af o rt h er e a s o n sg i v e nb e l o w .T h ei n f o r -
mation on cancer as the main cause of death, that
forms the basis for the terminal cancer recurrence rate
estimation, is being verified against the Czech Database
of Death Records and as such can be regarded as
highly reliable [38]. Moreover, there are standardised
procedures for control of the CNCR records against
the health care documentation implemented in both
the central and regional data management system of
the CNCR [12].
Regarding the CNCR Follow-up Reports that form the
basis for the non-terminal cancer recurrence rate esti-
mation, the main problem is a non-negligible proportion
of incomplete records with missing information on the
applied anti-tumour therapy. In total, 16% of all CRC
patients included in this study have missing information
on their treatment after the primary therapy. Indeed,
this proportion varies with stage and age when it ranges
from 6% in elderly patients diagnosed with stage IV
CRC to 22% in patients aged 50-64 years and diagnosed
with stage I or II CRC. This fact may lead to underesti-
mation of the true non-terminal recurrence rate as we
can assume that some of the patients with incomplete
Follow-up Reports were, in fact, treated. From this point
of view, the number of patients estimated to suffer from
the non-terminal CRC recurrence presented in this
paper can be regarded as a lower bound of the true
number of patients that will have to be treated in the
future. On the other hand, this problem concerns only
the population data and not the proposed methodology.
The cancer recurrence rates can be provided to the
model from any other source, for example from hospital
data.
Our estimates of colorectal cancer recurrence rates
are incomparable with studies that have presented data
on cancer recurrence together for all stages [5,7] due
to the unknown distribution of individual stages in
these studies. On the other hand, our results are fully
comparable with the cumulative recurrence rates
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of Manfredi et al. [37]. Our results are concordant
with this study, when considering the cancer recur-
rence in a form of distant metastases. However,
regarding 5-year local recurrence rates, our recurrence
estimates are higher than those published by Manfredi
and colleagues. This can be explained by two factors.
First, the differences in the Czech and French health
care systems may play a role as well as different
patient and tumour characteristics. Second, the use of
surrogate information for the identification of non-
terminal recurrence rates may influence the results,
because this information may not fully mirror the
patient’s true health status. Nevertheless, our results
show that there is a non-zero risk of cancer recurrence
even five years after diagnosis, i.e. after the period that
has been previously considered as a minimum time for
the so-called statistical cure of colorectal cancer [39].
This finding was also reported for rectal cancer [33].
However, future verificationo nap o p u l a t i o n - b a s e do r
hospital-based level with sufficiently long-term follow-
up would be of great value.
Considering the most recent changes in CRC epide-
miology and care in the Czech Republic, we feel that
t h em o s tl i k e l ys c e n a r i of o rt h ey e a r2 0 1 5i st h eo n e
with stabilised incidence rates, improving survival rates,
and an increasing proportion of treated patients (see
Table 2, scenario 6). The stabilised incidence rates can
be expected due to the increase in attendance at the
national organised screening program that has been
observed during very recent years in the Czech Republic
[40]. In addition, both the improvement in survival rates
and the increasing proportion of treated patients can be
attributed to the establishme n to fan e t w o r ko fh i g h l y
specialised Cancer Centres that took place in the Czech
Republic in 2006 [41], and the introduction of molecular
targeted therapy in recent years.
Conclusions
A new model for the estimation of the number of CRC
patients requiring active anti-tumour therapy in a stage-
specific manner utilizing solely the population-based
cancer registry data is proposed in this paper. In total,
eight scenarios concerning progress in incidence rates,
survival rates, and the probability of an anti-tumour
therapy administration are considered for the estimation
of the number of potentially treated CRC patients.
Based on the scenarios, the model predicts an increase
in CRC prevalence ranging from 13% to 30% in compar-
ison with the situation in 2008. The model also predicts
that the number of colorectal cancer patients requiring
active anti-tumour therapy in the Czech Republic in
2015 ranges from 10,074 to 11,440. Moreover, 3,485 to
4,469 patients will be treated for the metastatic disease,
which accounts for more than one third of all CRC
patients.
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